BIST10014.092,02▼ 0.00%Dollar's Vulnerability to AI Pullback: Apollo's Warning Creates Mixed Market ImpactUSD/TRY47.2346▲ 0.20%Blue Jays' Playoff Push Faces Hurdles as Hoffman's Struggles PersistEUR/TRY53.6987▲ 0.30%When Memecoins Rule Robinhood Chain, Where Do Tokenized Stocks Stand?BTC/USD$62,798.01▼ -2.20%US Boomers' Retirement Net Worth: Critical Differences Between $750K, $2M and $5MGOLD6.093,73▲ 0.15%BIST 100 Closes Lower: Technical Correction and Profit TakingBRENT$79.58▼ 0.00%Erdogan's NATO Summit Statements: Turkey's Diplomatic Power and Market Implications Financial Times Digital Subscription Strategies: 20% Discount on Annual Plans and Corporate SolutionsBIST10014.092,02▼ 0.00%Dollar's Vulnerability to AI Pullback: Apollo's Warning Creates Mixed Market ImpactUSD/TRY47.2346▲ 0.20%Blue Jays' Playoff Push Faces Hurdles as Hoffman's Struggles PersistEUR/TRY53.6987▲ 0.30%When Memecoins Rule Robinhood Chain, Where Do Tokenized Stocks Stand?BTC/USD$62,798.01▼ -2.20%US Boomers' Retirement Net Worth: Critical Differences Between $750K, $2M and $5MGOLD6.093,73▲ 0.15%BIST 100 Closes Lower: Technical Correction and Profit TakingBRENT$79.58▼ 0.00%Erdogan's NATO Summit Statements: Turkey's Diplomatic Power and Market Implications Financial Times Digital Subscription Strategies: 20% Discount on Annual Plans and Corporate Solutions

Global MarketsJuly 13, 2026 at 05:09 PM

TGTX: 46% Surge on Briumvi Outperformance, ClearBridge's SMID Strategy Highlights 2026's Top Picks

724FinanceGökberk Uçar

TGTX: 46% Surge on Briumvi Outperformance, ClearBridge's SMID Strategy Highlights 2026's Top Picks

TG Therapeutics (TGTX) surged 46% as its key drug Briumvi outperformed expectations. ClearBridge Investments' SMID Cap Growth Strategy highlighted TG Therapeutics as a top biotech performer in 2026. The company achieved a 13.56% monthly and 46.76% year-to-date gain, driven by Briumvi sales and positive clinical results for a subcutaneous version of the therapy. While the Russell 2500 Growth Index rose 24%, ClearBridge's strategy underperformed due to underweighting in AI infrastructure. TG Therapeutics' $8.74 billion market cap solidifies its leadership in multiple sclerosis treatments.

ClearBridge's strategy underscores TG Therapeutics' potential for expanded market reach. The stock is seen as a lower-risk long-term play compared to other AI-focused equities, benefiting from its commercial-stage position and therapeutic diversity.